Loading clinical trials...
Loading clinical trials...
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults
Conditions
Interventions
co-administration of cefepime and nacubactam
co-administration of aztreonam and nacubactam
+1 more
Locations
61
Bulgaria
Meiji Research Site
Pleven, Bulgaria
Meiji Research Site
Rousse, Bulgaria
Meiji Research Site
Silistra, Bulgaria
Meiji Research Site
Sofia, Bulgaria
Meiji Research Site
Beijing, China
Meiji Research Site
Changchun, China
Start Date
May 23, 2023
Primary Completion Date
November 22, 2024
Completion Date
November 26, 2024
Last Updated
December 24, 2025
NCT05639933
NCT07478510
NCT07406893
NCT06587113
NCT06860763
NCT04876131
Lead Sponsor
Meiji Seika Pharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions